Treatment of Palmoplantar Psoriasis
For palmoplantar psoriasis, start with high-potency topical corticosteroids (class 1) combined with calcipotriene for mild-to-moderate disease, and escalate to IL-17 inhibitors (secukinumab or ixekizumab) or IL-23 inhibitors (guselkumab) for moderate-to-severe or refractory disease.
Stepwise Treatment Algorithm
First-Line: Topical Therapy
Begin with ultrahigh potency (class 1) topical corticosteroids as the foundation of treatment 1. The AAD-NPF guidelines support this approach for localized disease 1. While the guideline evidence focuses on combination with systemic agents, topical corticosteroids remain the standard initial approach for palmoplantar variants 2, 3.
Second-Line: Phototherapy
If topicals fail after 8-12 weeks, consider phototherapy options:
- Excimer laser shows the highest efficacy with PPPASI-75 of 95% for severe disease 4
- PUVA with retinoids or fumaric acid esters achieves PPPASI-90 of 90% and 81.8% respectively for milder disease 4
Third-Line: Systemic Biologics
For palmoplantar plaque psoriasis (non-pustular):
The most recent network meta-analysis (2023) provides clear hierarchy 5:
- Secukinumab (IL-17A inhibitor) exhibits the highest probability of inducing complete resolution 5
- Ixekizumab (IL-17A inhibitor) ranks best for PPASI50 and PPASI75 5
- Infliximab also ranks highly for PPASI improvement but has practical limitations 5
For palmoplantar pustular psoriasis:
- Guselkumab (IL-23 inhibitor) has the strongest evidence for palmoplantar pustulosis 5, 4
- Bimekizumab (dual IL-17A/F inhibitor) shows remarkable results with 17 of 21 patients (81%) achieving complete clearance (IGA 0) within 1-4 months in the most recent 2024 case series 6
- Brodalumab and apremilast show PPPASI-50 ranging from 57.4-78.3% at week 16 4
Emerging Evidence: Bimekizumab Priority
The 2024 French multicenter case series demonstrates that bimekizumab may be the most effective option for severe palmoplantar pustular psoriasis, particularly in treatment-refractory cases 6. All 21 patients had failed median 3 prior systemic treatments, yet 81% achieved complete clearance. This dual IL-17A/F blockade addresses the synergistic IL-17/IL-36 inflammatory loop specific to palmoplantar pustular disease 6.
Combination Therapy Recommendations
When escalating to biologics for moderate-to-severe disease:
- Adding class 1 topical corticosteroid to etanercept for 12 weeks is recommended (Strength A) 1
- Adding calcipotriene/betamethasone to adalimumab for 16 weeks accelerates plaque clearance (Strength B) 1
- All topical corticosteroids can be combined with any biologic (Strength C) 1
Critical Clinical Considerations
Functional impairment supersedes body surface area in palmoplantar psoriasis 3. Even though lesions are localized to 3-4% of body surface, the fissuring, hyperkeratosis, and tissue hardening severely impact daily activities and occupational function 3. This justifies aggressive systemic therapy earlier than traditional severity measures would suggest.
Distinguish pustular from non-pustular variants as they have different pathophysiology and treatment responses 2, 7. Pustular variants respond better to IL-23 inhibitors (guselkumab) and dual IL-17 inhibitors (bimekizumab), while non-pustular plaque-type responds best to IL-17A inhibitors (secukinumab, ixekizumab) 5, 4.
For Japanese patients or those with focal infections, evaluate for triggering factors including dental infections, tonsillitis, or sinusitis, as these are present in approximately 80% of palmoplantar pustulosis cases and require different therapeutic algorithms 7.
Agents to Avoid or Use Cautiously
Based on 2024 systematic review evidence, anakinra, secukinumab (for pustular variant), spesolimab, and RIST4721 failed to achieve primary outcomes in recent trials and should not be first-line 4.
Risankizumab shows promise in case reports for rapid clearance 8, but lacks the robust evidence of guselkumab for pustular variants or secukinumab/ixekizumab for plaque-type disease.
Adverse Event Monitoring
With bimekizumab, monitor for candidiasis (19% incidence), though all cases respond to oral antifungals without requiring drug discontinuation 6.